Abstract
Background: Glottis laryngeal carcinoma at its early stage presents a critical challenge in balancing effective treatment with preserving the patient’s quality of life. This study explores the impact of rosiglitazone, a thiazolidinedione with potential anti-cancer properties, on both the quality of life and prognosis of patients diagnosed with early-stage glottic laryngeal carcinoma.
Aim: The primary aim of this research is to investigate whether the incorporation of rosiglitazone into the treatment protocol for early-stage glottic laryngeal carcinoma positively influences patient-reported quality of life measures. Additionally, the study seeks to assess the impact of rosiglitazone on the clinical prognosis and survival outcomes of patients with this specific cancer subtype.
Methods: A randomized controlled trial will be conducted involving patients diagnosed with early-stage glottic laryngeal carcinoma. Participants will be divided into two groups, one receiving standard treatment and the other receiving standard treatment with the addition of rosiglitazone. Quality of life assessments will be conducted using standardized tools, and clinical outcomes, including survival rates and disease progression, will be monitored over a specified follow-up period.
Results: The study’s results will provide insights into the effects of rosiglitazone on the quality of life of patients with early-stage glottic laryngeal carcinoma. Additionally, the clinical data collected will contribute to understanding the potential influence of rosiglitazone on the prognosis and survival outcomes in this patient population.
Conclusion: The findings from this research have the potential to inform clinical practice by offering evidence on whether rosiglitazone, when integrated into the treatment regimen, can enhance the quality of life and positively impact the prognosis of individuals diagnosed with early-stage glottic laryngeal carcinoma. Such insights may contribute to the development of more tailored and effective treatment approaches for this specific cancer subtype.
Keywords:
Glottic laryngeal carcinoma, early stage, rosiglitazone, quality of life, prognosis, clinical outcomes, randomized controlled trial, cancer treatment.